Jefferies upbeat on Australia's Integral Diagnostics' FY26 EBITDA outlook

Integral Diagnostics

07/04/2025 22:24

** Analysts at Jefferies say several factors have the potential to lead to an upside for Integral Diagnostics' IDX.AX FY26 EBITDA estimates

** Brokerage says potential factors include upgrading of Partial to Full MRI Licences, which could drive MRI volumes, as well as lung cancer screening

** Jefferies maintains PT at A$3.60/shr and "buy" rating for stock

** IDX has 16 partial licences that will be upgraded — which should drive MRI volume, thereby increasing co's market share of MRIs by 183bp to 10.3% — brokerage

** All 13 analysts covering stock rate "buy" or higher; their median PT is A$3.10 — LSEG data

** Stock down 10% YTD, as of last close

(Reporting by Shivangi Lahiri in Bengaluru)

((shivangi.lahiri@thomsonreuters.com))